Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.73 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.73 |
| ▸ | MPO | P05164 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | KDM5A | P29375 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | OGG1 | O15527 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678949 | 0.85 | MPO (0.80) | HDAC3HDAC6NCOR2MPOCYP3A4 | |
| SCHEMBL343630 | 0.85 | MPO (0.80) | HDAC3HDAC6NCOR2MPOCYP3A4 | |
| SCHEMBL22608571 | 0.84 | HDAC6 (1.00) | HDAC3HDAC6NCOR2LOXL2 | |
| SCHEMBL11139882 | 0.84 | MPO (0.64) | HDAC3HDAC6NCOR2MPOCYP3A4 | |
| SCHEMBL28188923 | 0.83 | MPO (0.76) | HDAC3HDAC6NCOR2MPOCYP3A4 | |
| SCHEMBL13009911 | 0.83 | HDAC6 (0.68) | HDAC3HDAC6NCOR2BLMPMP22 | |
| SCHEMBL7320693 | 0.83 | HDAC6 (0.68) | HDAC3HDAC6NCOR2MPOCYP3A4 | |
| SCHEMBL2643238 | 0.83 | PLK1 (0.68) | HDAC3HDAC6NCOR2LOXL2CA2 | |
| SCHEMBL1364607 | 0.82 | MPO (0.61) | HDAC3HDAC6NCOR2MPOCYP3A4 | |
| SCHEMBL27556167 | 0.82 | MPO (0.61) | HDAC3HDAC6NCOR2MPOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304932-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS INVOLVING ENERGY TRANSFER DYE CONJUGATES AND ANALYTES COMPRISING THE SAME | Life Technologies Corporation | 2023-09-28 | — | — | US | disclosed |
| US-11053279-B2 | Methods for the site-selective coupling of a first agent to a second agent | UNIVERSITEIT GENT (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20190002494-A1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | UNIVERSITEIT GENT (BE) | 2019-01-03 | — | — | US | disclosed |
| CN-108137518-A | As 6 inhibitor of histone deacetylase 1,3,4- oxadiazole derivatives compound and include its pharmaceutical composition | 株式会社钟根堂 | 2018-06-08 | — | — | CN | disclosed |
| CN-102046627-B | GABAAReceptor modulators | FORSKARPATENT I SYD AB | 2013-09-04 | — | — | CN | disclosed |
| CN-102046627-A | GABAAReceptor modulators | FORSKARPATENT I SYD AB | 2011-05-04 | — | — | CN | disclosed |
| EP-1691845-A4 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1691845-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | Bristol-Myers Squibb Pharma Company (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023314-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
| US-6534041-B1 | Having little or no fluorescence emission until dye is cleaved from construct at tumor or inflammation target site | INSTITUTE FOR DIAGNOSTIC RESEARCH GMBH OF THE FREE UNIVERSITY OF BERLIN (DE) | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053279-B2 | Methods for the site-selective coupling of a first agent to a second agent | PAICS, HNMT, DPYD | HDAC3 2865/4885HDAC6 2515/4885NCOR2 3751/4885 |
| US-20190002494-A1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | PAICS, HNMT, DPYD | HDAC3 2865/4885HDAC6 2515/4885NCOR2 3751/4885 |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | HDAC3 900/4885HDAC6 623/4885NCOR2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.